Preoperative Risk Stratification in Endometrial Cancer for Tailoring Lymph Node Staging (PRSTEC_multipr)
Preoperative Risk Stratification in Endometrial Cancer Using Expert Ultrasound and Molecular Classification for Tailoring Lymph Node Staging: Multicentric Prospective Observational Study
The goal of this observational study is to evaluaty the accuracy of current risk stratification of patients with endometrial cancer and to redefine lymph node staging recommendations based on real-world clinical data. The main question it aims to answer is:
Is there any group of patients who doesn't need lymph node staging for proper indication of adjuvant treatment? Participants are note taking any intervention. They are treated according to current standard of care and followed 3-years after primary surgery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Hradec Králové, Czechia
- Recruiting
- University hospital Hradec Králové
-
Contact:
- Petra Bretova
- Phone Number: +420777679238
- Email: bretova.petra@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women ≥18 years with newly diagnosed endometrial cancer (any histology)
- Undergoing primary surgical management
- Preoperative expert ultrasound, CT scan (could be waived in low risk cases)
- Preoperatively early-stage (stage I-II) of EC
- SLN mapping attempted intraoperatively
- FFPE tumor tissue available for molecular and IHC testing from biopsy
- Signed informed consent with the participation in the study
Exclusion Criteria:
- Neoadjuvant treatment
- Recurrent or metastatic disease at diagnosis
- Inadequate imaging or tissue samples
- Cancer synchronous duplicity
- Prior oncological treatment within the last five years
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The accuracy of preoperative risk stratification
Time Frame: From enrollment to the first follow-up visit at 4 weeks after surgery.
|
From enrollment to the first follow-up visit at 4 weeks after surgery.
|
|
Determination of specific groups for whom: 1) lymph node staging is crucial for changing risk category and adjuvant treatment decisions, and 2) lymph node staging could be safely omitted
Time Frame: From enrollment to the first follow-up visit at 4 weeks after surgery.
|
From enrollment to the first follow-up visit at 4 weeks after surgery.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 202511P08
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Cancer
-
NCT03621904RecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IV
-
NCT03580421CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage II
-
NCT07514078Not yet recruitingTreatment Endometrial Cancer
-
NCT07062016RecruitingEndometrial Carcinoma | Stage III Endometrial Cancer | Stage IV Endometrial Cancer | Endometrial High Grade Endometrioid Adenocarcinoma | Stage II Endometrial Cancer
-
NCT04917341CompletedGynecologic Cancer | Endometrial Cancer Stage
-
NCT07634601Not yet recruitingRecurrent Endometrial Carcinoma | Advanced Endometrial Carcinoma | Metastatic Endometrial Carcinoma | Stage III Endometrial Cancer | Stage IV Endometrial Cancer
-
NCT01289041CompletedAdvanced Endometrial Cancer
-
NCT00377520CompletedNeoplasms | Urogenital Neoplasms | Neoplasms by Site | Uterine Neoplasms | Genital Neoplasms, Female | Endometrial Neoplasms | Endometrial Cancer | Endometrium Cancer | Cancer of Endometrium | Cancer of the Endometrium
-
NCT01267357CompletedSerous Papillary Endometrial Cancer
-
NCT04792749RecruitingEndometrial Cancer Stage I
Clinical Trials on No Intervention: Observational Cohort
-
NCT06686342RecruitingHead and Neck Squamous Cell Carcinoma | Patient Derived Organoid | Drug Sensitive Test in Vitro
-
NCT07601152Not yet recruiting
-
NCT07597707Recruiting
-
NCT07545993Not yet recruitingNEC - Necrotizing Enterocolitis
-
NCT07490093Not yet recruitingSmell Disorder | Taste Alterations | Eating Behavior Changes
-
NCT07481188RecruitingFrailty and Nottingham Hip Fracture Score for Predicting 90-Day Mortality After Hip Fracture SurgeryFrailty | Hip Fracture | Proximal Femur Fracture
-
NCT07463898Not yet recruitingPreeclampsia (PE) | Cardiovascular Biomarkers | Preeclampsia (PE) Risk
-
NCT07426991RecruitingMultiple Sclerosis | Fatigue Syndrome, Chronic | Sleep Disorders | Primary Progressive Multiple Sclerosis | Secondary Progress Multiple Sclerosis | Remitting-Relapsing Multiple Sclerosis
-
NCT07422090Recruiting
-
NCT07414160Not yet recruitingCritical Illness | Adult | ICU